Hologic and Gen-Probe Announce Expiration of Hart-Scott-Rodino Act Waiting Period

Hologic, Inc. (Hologic)

and Gen-Probe Incorporated (Gen-Probe)

today announced that, in connection with Hologic's proposed acquisition of Gen-Probe, the initial 30-day waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired without a request for additional information from the Federal Trade Commission. Expiration of the waiting period satisfies a condition to close the proposed acquisition. As previously announced on April 30, 2012, Hologic agreed to acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash. The all-cash transaction is expected to be funded through available cash and additional financing provided by term loans and high yield securities. The transaction is expected to be completed in the third quarter of calendar 2012.